Factors Influencing a Specific Pathologic Diagnosis of Non-Small-Cell Lung Carcinoma

被引:6
作者
Sulpher, Jeffrey A. [1 ]
Owen, Scott P. [2 ]
Hon, Henrique [2 ]
Tobros, Kimberly [2 ]
Shepherd, Frances A. [2 ]
Sabri, Elham [3 ]
Gomes, Marcio [4 ]
Sekhon, Harman [4 ]
Liu, Geoffrey [2 ]
Canil, Christina M. [1 ]
Wheatley-Price, Paul [1 ]
机构
[1] Univ Ottawa, Dept Med, Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada
[2] Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Div Med Oncol & Hematol,Dept Med, Toronto, ON M5S 1A1, Canada
[3] Univ Ottawa, Res Inst, Ottawa Hosp, Ottawa, ON, Canada
[4] Univ Ottawa, Dept Pathol & Lab Med, Ottawa Hosp, Ottawa, ON, Canada
关键词
Chart review; Diagnosis; Histology; Non-small-cell lung cancer; CANCER; CHEMOTHERAPY; MUTATIONS; GEFITINIB; CYTOLOGY; EGFR; ADENOCARCINOMA; CLASSIFICATION; CARBOPLATIN; PACLITAXEL;
D O I
10.1016/j.cllc.2012.11.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pathologic subtyping of non-small-cell lung carcinoma is increasingly important when selecting therapy. The records of 739 patients were reviewed to identify factors associated with attaining a specific pathologic diagnosis. Only 456 (62%) of patients received a specific pathologic diagnosis, which was significantly associated with histologic biopsy samples, immunohistochemical testing, and diagnosis outside of an academic center. Introduction: Historically, a non-small-cell lung carcinoma diagnosis, without pathologic subclassification, provided sufficient information to guide therapy. Evidence now demonstrates that pathologic subtype classification is central in selecting optimal treatment. This review aimed to identify factors associated with a specific pathologic diagnosis. Methods: All nonoperative cases of non-small-cell lung carcinoma (NSCLC) referred to the medical oncology divisions of the Ottawa Hospital Cancer Centre (2008) and Princess Margaret Hospital, Toronto (2007-2010) were identified. The charts were reviewed for demographics, diagnostic methods, and final diagnosis. Logistic regression was performed to identify variables associated with a specific diagnosis. Results: Of 739 patient records analyzed, 377 (51%) were men, 299 (40%) were aged over 70 years, and 510 (69%) had an Eastern Cooperative Oncology Group performance status of 0-2. Three hundred and eighty five (52%) of patients were diagnosed in a tertiary academic center. The lung primary was sampled in 503 (68%) of patients. Computed tomography-guided biopsy (n = 370, 50%) and bronchoscopy (n = 179, 24%) were the most common techniques. Four hundred and seventy seven (65%) of biopsies were cytologic specimens alone, and immunohistochemistry was performed in 337 (46%) of cases. The most common diagnoses were adenocarcinoma (n = 338, 46%), NSCLC not otherwise specified (n = 254, 34%), and squamous cell carcinoma (n = 115, 16%). Overall, 456 (62%) of patients received a specific pathologic diagnosis. Factors significantly associated with attaining a specific pathologic diagnosis were diagnosis outside an academic center (adjusted odds ratios [OR] 2.1 [95% CI, 1.41-3.14]; P = .0003), histologic laboratory samples (adjusted OR 1.58 [95% CI, 1.003-2.49]; P = .049), and immunohistochemical testing (adjusted OR 1.82 [95% CI, 1.25-2.70], P = .0021). Conclusions: A significant minority of patients with NSCLC do not receive a specific pathologic diagnosis. In an era of individualized medicine, this may potentially impact optimal clinical management. Clinical Lung Cancer, Vol. 14, No. 3, 238-44 (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:238 / 244
页数:7
相关论文
共 50 条
  • [31] Targeted therapy of non-small-cell lung carcinoma
    Tiwari, Divya
    Brodie, Seth A.
    Brandes, Johann C.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2012, 6 (01) : 41 - 56
  • [32] Personalized choice of maintenance therapies in non-small-cell lung cancer
    Blais, N.
    Corrales-Rodriguez, L.
    CURRENT ONCOLOGY, 2012, 19 : S64 - S72
  • [33] Adjuvant Chemotherapy for Completely Resected Non-Small-Cell Lung Cancer
    Suehisa, Hiroshi
    Toyooka, Shinichi
    ACTA MEDICA OKAYAMA, 2009, 63 (05) : 223 - 230
  • [34] Salvage treatment with apatinib for advanced non-small-cell lung cancer
    Song, Zhengbo
    Yu, Xinmin
    Lou, Guangyuan
    Shi, Xun
    Zhang, Yiping
    ONCOTARGETS AND THERAPY, 2017, 10 : 1821 - 1825
  • [35] Second-line erlotinib for non-small-cell lung cancer
    Lorusso, Vito
    Cinieri, Saverio
    LANCET ONCOLOGY, 2012, 13 (04) : E141 - E142
  • [36] The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer
    Srinivasamaharaj, Srividya
    Salame, Bilal Khameze
    Rios-Perez, Jorge
    Kloecker, Goetz
    Perez, Cesar A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (12) : 1227 - 1233
  • [37] Impact of Non-Small-Cell Lung Cancer-Not Otherwise Specified Immunophenotyping on Treatment Outcome
    Righi, Luisella
    Vavala, Tiziana
    Rapa, Ida
    Vatrano, Simona
    Giorcelli, Jessica
    Rossi, Giulio
    Capelletto, Enrica
    Novello, Silvia
    Scagliotti, Giorgio V.
    Papotti, Mauro
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (10) : 1540 - 1546
  • [38] The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib
    Grossi, Francesco
    Rijavec, Erika
    Dal Bello, Maria Giovanna
    Defferrari, Carlotta
    Brianti, Annalisa
    Barletta, Giulia
    Genova, Carlo
    Murolo, Carmelina
    Cosso, Maurizio
    Fontanini, Gabriella
    Boldrini, Laura
    Truini, Mauro
    Pronzato, Paolo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1407 - 1412
  • [39] Gefitinib for non-small-cell lung cancer treatment
    D'Incecco, Armida
    Cappuzzo, Federico
    EXPERT OPINION ON DRUG SAFETY, 2011, 10 (06) : 987 - 996
  • [40] Vandetanib for the treatment of non-small-cell lung cancer
    Wong, Hui-li
    de Boer, Richard H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (14) : 2271 - 2278